Molly Keane, Senior Manager Patient Advocacy at Amgen, shared a post on LinkedIn:
“Thanksgiving is always a moment for me to pause and appreciate the extraordinary people in my life, including this LinkedIn community. I’m fortunate to have a wide and generous network here, and today I’m turning to you with deep hope and gratitude. If you or your teams are recruiting for oncology clinical trials, I’m asking from the bottom of my heart to please read this and share anything you may know that could help my dear friend.
I met Elaine, pictured here at the center, in 2021 when our neighborhood found connection through outdoor meetups with our COVID babies. What began as a search for community became the start of a friendship I treasure. Even then, she was already a survivor, having overcome one battle with cancer and actively fighting a second.
Now, in 2025, Elaine is facing her third cancer diagnosis at just 36 years old. To call it unfair doesn’t even scratch the surface. Yet through every setback these last 11 months, she has remained a bright, steady light especially for her sweet three-year-old son.
We are urgently seeking a clinical trial that could save Elaine’s life. If you have any insight, any connection, any study that might be a fit, I would be profoundly grateful for your help. Please take a look at the information below, and feel free to repost, share widely, or amplify in any way you can.
We need a truly big, united community behind this one—and I’m so grateful to each of you who take a moment to read, reflect, and help us search for hope.
Here are the details…
Medical Summary:
EY is a 36 year old female with ER<1% PR<1% HER2 0. FISH negative metastatic breast cancer to the lungs, bone, liver, brain, and subcutaneous nodules. Her brain metastases are treated and her cancer is PDL1 negative. Additional histology/NGS from the most recent solid tumor biopsy on 6/12/2025 include TP53 Y236N, PTEN deep deletion, 4. Mutations/Mb (UCSF500). Her Guardant liquid biopsy from 2/12/2025 indicated TP53 Y236N 53%, CCND1 amplified, EGFR amplified, PIK3CA amplified. Additionally, her biopsy was tested for nectin-4 and was negative. No other mutations noted and she has not received immunotherapy or PARP inhibitors at any point. 1L Kisqali/Letrozole/Lupron showed immediate progression that resulted in hospital stay and radiation, 2L Enhertu showed progression after 3 cycles, 3L GemCarbo was initiated on 6/24/25, PETCT on 11/13/2025 indicated progression, resulting in initiation of 4L Eribulin on 11/14/2025. Her ECOG score is 1 and zipcode is 94598 but willing to relocate for trials.
Current Approach:
Open to both TNBC-only trials and basket trials, with a preference for TNBC only trials. Would like to prioritize novel therapies that are Phase 2b and above sponsored by a major pharmaceutical company, hospital, or NIH/NCI. Phase 1b is okay if it is a promising radioligand therapy or it is anything that allows active CNS involvement. Additionally, interested in cell therapy trials that show promise for TNBC.”